News
- Author:
- Andrew D. Bowser
Publish date: May 28, 2021
High-dose dual therapy had the lowest frequency of adverse events, but significantly lower eradication rates versus hybrid or quadruple therapies, ...
News
- Author:
- Andrew D. Bowser
Publish date: May 27, 2021
Hepatitis C virus infection no longer confers worse patient survival in the era of DAA therapy, but the population remains underserved.
News
- Author:
- Andrew D. Bowser
Publish date: May 27, 2021
Better inclusion of underrepresented minorities in clinical trials is critical to reducing health care disparities and improving patient outcomes.<...
News
- Author:
- Andrew D. Bowser
Publish date: May 26, 2021
IBS symptoms were expected to worsen, fueled by new stresses and pressures related to the nationwide lockdown, but now that hypothesis has changed....
News
- Author:
- Andrew D. Bowser
Publish date: May 26, 2021
IBS symptoms were expected to worsen, fueled by new stresses and pressures related to the nationwide lockdown, but now that hypothesis has changed....
News
- Author:
- Andrew D. Bowser
Publish date: May 26, 2021
These data clearly highlight the need to step up efforts to help level gastrointestinal cancer disparities, commented Dr. Byron Cryer.
News
- Author:
- Andrew D. Bowser
Publish date: May 13, 2021
Finding holds true for men and women, even for those individuals with BMIs in the high-normal range.
News
- Author:
- Andrew D. Bowser
Publish date: May 6, 2021
Study findings also support the feasibility of moderate to vigorous exercise interventions even in individuals with obesity who had a very low leve...
News
- Author:
- Andrew D. Bowser
Publish date: December 11, 2020
A 74% complete response rate is encouraging in interim analysis of the phase 2 study, but requires further follow...
News
- Author:
- Andrew D. Bowser
Publish date: December 10, 2020
Durable responses were seen among patients with follicular lymphoma and diffuse large B-cell lymphoma, an investi...
News
- Author:
- Andrew D. Bowser
Publish date: December 7, 2020
Toxicities were manageable in the ongoing dose-expansion phase, which is expected to complete enrollment in Febru...
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2020
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to be...
News
- Author:
- Andrew D. Bowser
Publish date: December 6, 2020
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months follow...
News
- Author:
- Andrew D. Bowser
Publish date: December 5, 2020
Preliminary data support “emerging consensus” of substantial morbidity and mortality but do not support treatment...
Article
- Author:
- Andrew D. Bowser
Publish date: October 28, 2020
ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.
